1092-内吞逃逸介导的癌症ADC治疗耐药机制研究 episode artwork

EPISODE · Jun 7, 2026 · 23 MIN

1092-内吞逃逸介导的癌症ADC治疗耐药机制研究

from 聊聊Sci

这项研究通过单细胞测序与空间转录组技术,揭示了膀胱癌对NECTIN4-ADC(维恩妥珠单抗)产生耐药的新机制。研究发现,一类高表达NECTIN4靶点但仍具耐药性的肿瘤细胞通过激活ELF3转录因子,诱导了AKR1C1的表达。AKR1C1不仅干扰了细胞对药物的内吞摄取,还协同WWP2蛋白通过细胞外囊泡(EVs)将药物排出体外,从而逃避杀伤。研究进一步证实,使用AKR1C1抑制剂可以有效恢复肿瘤对ADC药物的敏感性。这一发现为克服临床中靶点高表达却不响应的耐药难题提供了潜在的治疗策略。References:Wang Y, Chen Z, Wang W, et al. Endocytic evasion confers resistance to antibody-drug conjugates therapy in cancer[J]. Cancer Cell, 2026.前往小宇宙评论区与主播互动

Episode metadata supplied by the publisher feed · Published Jun 7, 2026

Embed this episode

Ready to play

1092-内吞逃逸介导的癌症ADC治疗耐药机制研究

0:00 23:04

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of 聊聊Sci?

This episode is 23 minutes long.

When was this 聊聊Sci episode published?

This episode was published on June 7, 2026.

Can I download this 聊聊Sci episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!